Regenerative medicine aims to regenerate damaged tissues using autologous cell engraftment or taking advantage of the spontaneous proliferative potential of resident cells.
In heart, recent evidences converge to consider adult cardiomyocytes as the main source of cell renewal to regenerate heart tissue damaged by ischemia. However, due to the low rate of spontaneous cardiomyocyte proliferation, this process needs to be pharmacologically boosted using for instance growth factors such as neuregulin-1.Since neuregulin-1 is known to stimulate cell proliferation in non-cardiac tissue its safety for human cardiac regenerative medicine is questioned.
In this context, the proposal, using exogenous administration of IGF1 and transgenic mice with IGF1R deletion will evaluate the capability another candidate, IGF1, to stimulate resident adult cardiomyocytes proliferation without producing significant undesired proliferation in lung and liver.
This pilot study is a prerequisite for further ones that will demonstrate that IGF1 could be efficacious and safe for human heart failure treatment.